The review was published in Frontiers in Pharmacology on 22 October 2026. It is a critical narrative synthesis rather than a prospectively registered systematic review, and its authors searched PubMed, Web of Science, ScienceDirect, CNKI, Wanfang and reference lists through May 2026, followed by a targeted update through 18 August. They grouped evidence by experimental unit: complete-product studies, studies of individual ingredients or defined extracts, and adjacent research on related prescriptions, delivery systems or disease mechanisms. This hierarchy was designed to prevent findings about a purified compound or an authenticated plant material from being presented as proof that the complete capsule works. The review also had no duplicate independent screening, formal risk-of-bias instrument or new quantitative synthesis and therefore did not provide pooled effect estimates or grade certainty.

Within traditional Chinese medicine, ulcerative colitis has no exact one-to-one equivalent, but its symptoms overlap with categories such as dysentery, diarrhea and intestinal wind. The syndrome commonly called intestinal damp-heat describes frequent urgent stools containing mucus or blood, abdominal discomfort, tenesmus and a feeling of incomplete evacuation. The five materials are assigned complementary roles within that framework: Sophora flavescens is the principal heat-clearing and damp-drying ingredient; Sanguisorba officinalis is associated with cooling blood and reducing bleeding; Indigo naturalis is used for heat-clearing and blood-cooling functions; Bletilla striata contributes hemostatic and tissue-repair functions; and licorice is intended to harmonize the combination. These roles generate testable hypotheses, including whether control of bleeding is accompanied by reduced mucosal inflammation, rather than replacing biomedical diagnosis or established measures of disease severity.

The capsule is defined by both its ingredients and its pharmaceutical design. Its enteric coating is intended to protect the contents during passage through the upper gastrointestinal tract and increase delivery to the distal bowel. That design remains a formulation hypothesis rather than a demonstrated exposure profile. Active ulcerative colitis can alter transit and luminal pH, while fed conditions, proton-pump inhibitors, coating thickness and batch variability may also affect disintegration. The review therefore calls for sequential dissolution testing under gastric, small-intestinal and colonic conditions, stability data for intact capsules and, ideally, confirmation of release in humans. Measurements should extend beyond plasma because the relevant effects may arise from luminal action, mucosal exposure or systemic immune modulation. For a colon-targeted product, plasma concentration alone may underestimate mucosal exposure, while high systemic concentrations may be more relevant to toxicity.

Complete-formulation experiments offer more direct evidence than ingredient studies. In mouse models of chemically induced colitis, recognizable versions of the product have been associated with improvements in disease activity, colonic injury, inflammatory mediators, barrier proteins and microbial metabolites. More recent studies report a butyrate–GPR43–NCR-positive group 3 innate lymphoid cell axis, inhibition of NLRP3 inflammasome and STAT3-related signaling, changes in AGE-RAGE/NF-κB pathways, and ferroptosis-related endpoints. These findings connect microbial metabolism, epithelial integrity, inflammatory amplification and regulated cell death in biologically coherent ways. However, most experiments used small samples and acute disease models, administered treatment preventively or otherwise failed to reproduce clinical induction, and did not fully characterize the tested batches. Correlations between pathway markers and improved outcomes do not establish that each pathway is an independent target or causal mediator. Causal validation would require perturbations such as receptor antagonism, genetic manipulation, metabolite rescue or microbiota transfer.

Studies of individual ingredients broaden the biological plausibility while leaving the capsule’s effects unresolved. Matrine and oxymatrine have been associated in experimental systems with inflammatory signaling, oxidative stress, barrier protection and ferroptosis-related changes, and Sophora flavonoids have affected T-cell balance, epithelial pathways and microbial communities. Indigo naturalis, a processed source of indigoid compounds including indigo and indirubin, has shown short-term efficacy in a multicenter randomized trial involving people with active ulcerative colitis and may influence aryl hydrocarbon receptor pathways involved in mucosal defense. Sanguisorba extracts, Bletilla polysaccharides and licorice constituents have likewise produced supportive experimental findings. Yet these studies involve different doses, preparations, release profiles and safety conditions. Neither the presence of a compound in the capsule nor activity in a purified experimental system establishes that it reaches diseased tissue at a clinically relevant concentration or explains the complete product’s effect.

Clinical evidence comes mainly from older randomized studies. A multicenter single-blind trial reported efficacy for a composite Sophora colon-soluble capsule, and a later double-blind, double-dummy study involving 320 participants compared Fufangkushen colon-coated capsules with mesalazine over roughly eight weeks, finding broadly comparable short-term clinical and mucosal outcomes. Double-dummy masking is useful when dosage forms differ because it can help preserve participant and assessor blinding. However, a lack of a statistically significant difference does not prove equivalence unless an equivalence or noninferiority margin, adequate power, adherence, analysis population and confidence interval were specified in advance. The studies also had limited follow-up, older reporting standards and incomplete batch data. Meta-analyses reporting favorable “clinical effective rate” and traditional-pattern outcomes increase statistical precision but cannot remove small-study bias, selective publication, endpoint heterogeneity or uncertainty over whether different preparations were studied.

More recent clinical information remains provisional. A 2026 single-center cohort examined FSEC in combination with vedolizumab during induction and reported favorable week-14 clinical and endoscopic signals. Longer-term findings were sensitive to the analysis population, with a per-protocol signal not reproduced in the intention-to-treat analysis. Because treatment allocation was not randomized, baseline severity, clinician preference, affordability, prior response and adherence could have influenced the results; missing data could also have altered apparent durability. Such cohorts remain useful for feasibility, adherence, subgroup hypotheses and rare harms, but they cannot establish that FSEC adds benefit to biologic therapy. A prospective randomized add-on design would be needed to separate the capsule’s effect from concurrent treatment, regression to the mean and unequal follow-up.

Safety is particularly important because several ingredients carry recognizable hazards. Experimental matrine exposure has been linked to oxidative stress, mitochondrial apoptosis, disruption of Nrf2/GPX4 defenses, ferroptosis-related toxicity and altered cholesterol synthesis, although these findings cannot quantify clinical incidence in FSEC. Indigo naturalis has been associated with liver injury and pulmonary arterial hypertension, and ischemic colitis has also been reported during its use, a complication made difficult to recognize because worsening abdominal pain and bleeding can resemble an ulcerative colitis flare. Licorice metabolites can produce mineralocorticoid-like effects, including sodium retention, edema, hypertension, hypokalemia, metabolic alkalosis and arrhythmia. Risk may rise with prolonged use, older age, slow intestinal transit and exposure to other licorice products. Trials and pharmacovigilance should therefore document the exact product, batch, dose, duration, concomitant medicines and laboratory findings while actively monitoring liver chemistry, blood pressure, potassium, respiratory symptoms and cardiovascular events.

The review’s proposed next step is a linked chain from reproducible product to exposure, mechanism and clinical outcome. The first stage requires a reference dossier documenting botanical and processed-material identity, source, medicinal parts, preparation, excipients, quantitative multi-marker assays, chromatographic fingerprints, contaminants, stability and release performance. The same characterized batch should then be used for exposure studies, causal mechanism experiments and clinical assessment. A prospective multicenter randomized trial could evaluate clinical remission together with centrally read endoscopic improvement at week 8 or 12, with histology, fecal calprotectin, corticosteroid-free remission, quality of life, pharmacokinetics and safety as secondary outcomes. Maintenance follow-up would need to address relapse, hospitalization, colectomy and cumulative adverse events. Until such evidence is available, the review concludes that FSEC is a plausible and testable colon-targeted ethnopharmacological intervention, not a proven replacement for standard ulcerative colitis care.

Subject of Research: Evaluation of a five-material enteric-coated Chinese patent medicine for ulcerative colitis

Article Title: Five-flavor Sophora flavescens enteric-coated capsules for ulcerative colitis: ethnopharmacological rationale, pharmacology, clinical evidence, and safety

Article References: Ma, C., & Yang, C. (2026). Five-flavor Sophora flavescens enteric-coated capsules for ulcerative colitis: ethnopharmacological rationale, pharmacology, clinical evidence, and safety. Frontiers in Pharmacology, 17, 1972684. https://doi.org/10.3389/fphar.2026.1972684

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1972684

Keywords: ulcerative colitis, Sophora flavescens, Wuwei Kushen, Chinese patent medicine, ethnopharmacology, gut microbiome, colon-targeted delivery, clinical trials, drug safety, inflammatory signaling, Five-flavor, Sophora

The investigation began with a pragmatic problem. Earlier work had shown that the chloroform fraction of G. thalictroides roots was strongly cytotoxic against cancer cell lines, and four active compounds had already been isolated, including two beta-carboline alkaloids and two cyclopeptides. But several minor metabolites visible in chromatographic profiles could not be captured in sufficient quantity for full structural elucidation. To close these gaps, the researchers re-extracted four kilograms of dried roots with ethanol, partitioned the resulting extract into hexane, chloroform, and ethyl acetate fractions, and prepared a traditional water decoction in parallel, mirroring exactly how local practitioners steep half a teaspoon of dried root in boiling water and drink it twice a day.

Before any purification began, the team mapped the plant’s entire metabolome using ultra-high-performance liquid chromatography coupled with high-resolution tandem mass spectrometry. The resulting data were assembled into a molecular network, a computational map in which each node represents a detected compound and edges connect molecules with similar fragmentation patterns. The network contained 2,066 nodes linked by 3,075 edges, and through in silico database searching combined with a taxonomically informed scoring filter, the team tentatively annotated 284 compounds, refining thirteen of them to metabolites previously reported in the Rubiaceae family. Distinct clusters emerged corresponding to indole alkaloids characteristic of the plant family and to the cyclopeptides already known from this species.

Armed with this map, the researchers then chased the actual molecules. Medium-pressure liquid chromatography with ultraviolet detection generated eighty-two fractions, many of which were further purified by semi-preparative HPLC, ultimately yielding twenty-six fully characterized compounds. The haul included phenolic glycosides, iridoids, coumarins, lignans, anthraquinones, and two important families of nitrogen-containing metabolites: Rubiaceae-type cyclopeptides of the bouvardin series and beta-carboline alkaloids. Three of the isolated compounds proved to be previously unknown natural products, and one anthraquinone, 1-methoxy-2,7-dihydroxyanthraquinone, was reported as a natural-source isolate for the first time.

The new cyclopeptides were the first major prize. Compound 18, named 5-beta-hydroxy-RA-XII, turned out to be a bouvardin-type cyclic hexapeptide bearing an appended glucose unit attached to the tyrosine-6 residue, a feature confirmed by nuclear magnetic resonance correlations from the sugar’s anomeric proton to the aromatic carbon of the tyrosine ring and by high-resolution mass spectrometry. Compound 19, dubbed 5-beta-hydroxy-RA-I, carries an additional oxygen relative to bouvardin: careful inspection of its spectra revealed that a methyl doublet belonging to the alanine-2 residue had vanished, replaced by an oxymethylene signal, indicating that an alanine had been converted to a serine. Both nomenclatures follow the RA-series convention established decades ago for related antitumor hexapeptides from Rubia species.

The most consequential chemical revision involved the beta-carboline alkaloids 24 and 25, which had been described in earlier studies of the same species. The original assignments posited two independent tertiary alcohols in the aliphatic side chain and treated key mass spectrometric ions as water-loss adducts. The new analysis flipped that interpretation. Instead, the team proposed that the two tertiary alcohols cyclize to form an internal ether, creating an extra five-membered ring, so that the observed ions correspond directly to protonated molecules. Carbon-13 chemical shift comparisons with structurally related ether-bridged compounds in the literature supported this reading, and the consistency of the proposed structures with all one- and two-dimensional NMR data was verified using the CT web application, which performs complete quantum mechanical spectral analysis, iteratively optimizing chemical shifts and coupling constants against calculated proton spectra.

Establishing the three-dimensional architecture demanded additional computational muscle. Relative configurations were locked down through nuclear Overhauser effect correlations, while absolute configurations were assigned by comparing experimental electronic circular dichroism spectra with spectra calculated for both candidate stereoisomers using time-dependent density functional theory. For the revised alkaloid 24, the experimental trace matched the 14R,15R,18S isomer. For the genuinely new alkaloid 23, which features an intramolecular ether bridge and a hydroxylated methine in a compact tetracyclic framework, the calculations pointed unambiguously to the 14S,15S,18R,19R configuration. Every structural claim in the paper therefore rests on converging lines of spectroscopic and computational evidence rather than a single technique.

With pure compounds in hand, the biological evaluation delivered striking results. Testing against BT-20 triple-negative breast cancer cells, an aggressive subtype lacking the three most common therapeutic targets, the bouvardin family dominated the potency rankings. Bouvardin itself and 6-O-methylbouvardin inhibited cell survival with IC50 values of roughly 0.25 micromolar, while 5-beta-hydroxy-RA-III followed at 2.7 micromolar. Structure-activity patterns emerged clearly: adding a hydroxyl group at the alanine-2 position reduced potency several-fold, and the bulky, highly polar glucose of compound 18 attenuated activity tenfold, plausibly by limiting cellular uptake. Anthraquinones showed moderate activity between 23 and 110 micromolar, and the beta-carbolines ranged from 65 to 193 micromolar, weaker but still biologically meaningful. Mechanistically, bouvardins are known inhibitors of protein biosynthesis, while anthraquinones can generate reactive oxygen species and form the scaffold of several approved anticancer drugs.

The beta-carbolines told a more intriguing mechanistic story. Because this scaffold had previously been shown to suppress Wnt signaling, a central oncogenic pathway implicated in tumor progression, therapy resistance, cancer stem cell maintenance, and epithelial-mesenchymal transition, the researchers ran a TopFlash reporter assay measuring Wnt3a-driven transcription in the same BT-20 cells. Compound 24 emerged as a selective Wnt pathway inhibitor with an IC50 near 40 micromolar, while its close analog 25, lacking the C-19 hydroxyl group, showed no specific Wnt inhibition at all. Compound 23 was entirely inactive, likely because its indole nitrogen is sequestered in an intramolecular cyclization and cannot engage biological targets. Both active and inactive derivatives were ten to twenty times less potent than the best Wnt-targeting beta-carbolines reported previously, so the authors are candid that these particular molecules are not optimal scaffolds, but the sharp activity difference between 24 and 25 provides a valuable structural clue about which molecular features matter for pathway inhibition.

Perhaps the most provocative conclusion concerns the plant as a whole. The cytotoxic bouvardins and the Wnt-selective beta-carboline coexist in the same chloroform fraction, and the authors argue that this combination may function as a multi-component anticancer system, with Wnt inhibition potentially sensitizing cancer cells to cytotoxic stress and simultaneous effects on tumor progression, recurrence, and apoptosis. Notably, the molecular network revealed that the cyclopeptides and beta-carbolines appear absent or only trace in the traditional water decoction, raising questions about which constituents actually reach patients drinking the remedy. The authors frame their findings as a foundation for pharmacological investigation, in vivo studies, and ultimately drug development, and the discovery of three new molecules, the correction of two flawed structures, and the demonstration of pathway-specific activity together make G. thalictroides one of the more compelling underexplored sources of anticancer natural products to emerge from Brazilian ethnobotany in recent years.

Subject of Research: Phytochemistry and anticancer bioactivity of Galianthe thalictroides metabolites

Article Title: Comprehensive phytochemical study of Galianthe thalictroides: isolation of three new compounds, structural revision of β-carbolines, and evaluation of cytotoxic and anti-wnt activities

Article References: Figueiredo, P. D. O., Kirchhoffer, O. A., Marcourt, L., Quiros-Guerrero, L., Koval, A., Kato Junior, W. H., Yoshida, N. C., Garcez, F. R., Garcez, W. S., Katanaev, V. L., Wolfender, J.-L., & Queiroz, E. F. (2026). Comprehensive phytochemical study of Galianthe thalictroides: isolation of three new compounds, structural revision of β-carbolines, and evaluation of cytotoxic and anti-wnt activities. Frontiers in Natural Products, 5, Article 1840056. https://doi.org/10.3389/fntpr.2026.1840056

Image Credits: AI Generated

DOI: 10.3389/fntpr.2026.1840056

Keywords: Galianthe thalictroides, natural products, cyclopeptides, beta-carboline alkaloids, Wnt signaling, cytotoxicity, triple-negative breast cancer, molecular networking, NMR, electronic circular dichroism, bouvardin, ethnopharmacology

The research began in the Talakona Forest of Chittoor district in Andhra Pradesh, India, at roughly 850 meters above sea level, where the roots were collected and taxonomically authenticated by a botanist at Sri Venkateswara University, with a voucher specimen deposited in the departmental herbarium. After washing, shade-drying, and grinding the material, the team split their extraction strategy in two. One portion was defatted with petroleum ether, yielding a pale green semisolid extract at just 1.15 percent by weight. The remaining defatted residue was exhaustively extracted with ethanol using maceration followed by Soxhlet extraction, producing a dark brown semisolid at a much richer 8.25 percent yield. That yield gap alone told the chemists something important: the polar chemistry of the root, the kind ethanol dissolves best, was where the bulk of the phytochemical action lay.

Qualitative screening confirmed the split. The petroleum ether extract contained mainly steroids, fixed oils, and fats, while the ethanol extract was a treasure trove of proteins, phenolic compounds, flavonoids, tannins, glycosides, and saponins. Quantitative analysis then put numbers on that richness. Using the Folin–Ciocalteu colorimetric assay with gallic acid as the reference standard, the team measured a total phenolic content of 80.12 milligrams of gallic acid equivalents per gram of extract. The aluminum chloride colorimetric method, calibrated against quercetin, gave a total flavonoid content of 1.33 milligrams of quercetin equivalents per gram, and a gravimetric acetone-precipitation method revealed a substantial saponin fraction of 18.50 percent by weight. All measurements were performed in triplicate with relative standard deviations below two percent, indicating solid analytical precision.

To map the chemical fingerprint of the ethanol extract more finely, the researchers turned to high-performance thin-layer chromatography, or HPTLC, a technique prized in natural product chemistry for its speed, low solvent consumption, and ability to resolve many samples on a single silica plate. Running the extract on silica gel 60 F254 plates in a toluene, ethyl acetate, and formic acid mobile phase, the CAMAG densitometry system resolved six distinct peaks with retention factor values ranging from 0.02 to 0.89. The most abundant constituent, at an Rf of 0.62, accounted for 18.14 percent of the total profile. Crucially, two of the observed Rf values matched those of authentic standards: quercetin at 0.44 and gallic acid at 0.51, two polyphenols with well-documented antioxidant and anti-inflammatory credentials. The authors note, however, that Rf matching alone is only putative identification, and definitive confirmation would require comparison with reference compounds and orthogonal spectroscopic techniques.

The heart of the study was the column chromatography campaign that followed. The ethanol extract was loaded onto a silica gel column and eluted with a gradient of increasing polarity, from pure petroleum ether through petroleum ether–ethyl acetate mixtures and finally into ethyl acetate–methanol blends. Roughly 85 to 95 fractions of 25 to 50 milliliters each were collected and monitored by thin-layer chromatography under ultraviolet light and after derivatization with anisaldehyde–sulfuric acid reagent. From fractions 7 through 12, eluted at 80:20 petroleum ether to ethyl acetate, repeated recrystallization from petroleum ether delivered 10 milligrams of a semisolid compound designated HM-1. Fractions 50 to 54 yielded a white crystalline solid, HM-2, purified from chloroform at 8 milligrams, and the highly polar fractions 80 to 85 gave a yellow amorphous powder, HM-3, recrystallized from ethyl acetate at 10 milligrams. Analytical HPLC confirmed each isolate was better than 95 percent pure.

Spectroscopy then took over. HM-1, with a molecular ion at m/z 310 and the formula C20H38O2, showed infrared absorptions for hydroxyl and carbonyl groups and proton NMR signals consistent with a long unsaturated aliphatic chain, leading to its tentative assignment as icos-10-enoic acid, a twenty-carbon monounsaturated fatty acid. HM-2, at m/z 405 and C22H44O6, displayed an anomeric proton signal and sugar-region carbon resonances alongside a long methylene chain and ether stretching bands, fitting the structure 2-(hexadecyloxy)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol, a glycoside-like molecule not previously reported from this species. HM-3, with a molecular ion at m/z 301, aromatic UV maxima, and NMR signals for hydroxyl groups and a methoxy substituent on a flavonoid scaffold, was identified as kaempferide, a methylated flavonol previously known from Alpinia officinarum rhizomes. The authors emphasize that all three assignments remain tentative pending high-resolution mass spectrometry and multidimensional NMR.

With three candidate molecules in hand, the team moved to the computational phase. They retrieved the crystal structure of human pancreatic lipase from the Protein Data Bank under the identifier 2PPL, prepared the protein in Schrödinger’s Maestro environment with the OPLS-AA force field, and verified its stereochemical quality with a Ramachandran plot showing 97 percent of residues in favored regions. Each ligand was energy-minimized and prepared with LigPrep and Epik to generate physiologically relevant ionization states, then docked into the enzyme’s binding site using the Glide Extra Precision protocol. All three compounds docked successfully into a single binding site. HM-2 led with a Glide score of minus 5.95 kilocalories per mole, driven by favorable van der Waals contacts, hydrogen bonding, and electrostatic interactions, including predicted hydrogen bonds to the residues aspartate 296 and asparagine 294 at distances of roughly 2 angstroms. Kaempferide followed closely at minus 5.77 kilocalories per mole, with strong hydrogen-bonding contributions to glutamine 320, cysteine 322, and aspartate 409. The fatty acid HM-1 lagged far behind at minus 2.90 kilocalories per mole.

The comparison with the clinical benchmark was sobering but instructive. When docked alongside orlistat, the only approved pancreatic lipase inhibitor on the market, sold as both Orlistat and Xenical, both HM-2 and HM-3 showed lower predicted binding affinities than the reference drug. The authors are candid about this gap, positioning their compounds not as ready-made drugs but as starting points for further investigation. On the pharmacokinetic side, QikProp-based ADMET predictions were broadly encouraging. Predicted octanol-water partition coefficients ranged from 2.4 to 4.2, polar surface areas stayed below the 140 square angstrom threshold for intestinal permeability, and all three compounds satisfied Lipinski’s Rule of Five. Predicted hERG channel values between minus 4.8 and minus 5.3 offered no obvious cardiac toxicity red flags, though the team stresses that such computational estimates cannot substitute for real pharmacokinetic and toxicological testing.

What makes the study notable is its methodological honesty in a field often prone to overclaiming. The authors repeatedly caution that docking scores are not evidence of enzyme inhibition, that ADMET predictions are theoretical, and that the anti-obesity potential of these molecules is entirely unproven. Earlier work by some of the same researchers had shown that Hiptage madablota affected high-fat diet-induced obesity in rats, providing a biological rationale for the current investigation, but the mechanistic link remains to be drawn. The road forward, as the authors lay it out, includes comprehensive LC-MS/MS and HPLC-PDA profiling of the extract, definitive structural confirmation of the isolates, and, most critically, experimental pancreatic lipase inhibition assays to test whether the predicted binding interactions translate into measurable enzyme blockade. If they do, this humble forest climber could earn a place in the growing arsenal of plant-derived leads being explored against one of the world’s most pressing metabolic epidemics.

Subject of Research: Phytochemical isolation and molecular docking of Hiptage madablota root compounds as predicted human pancreatic lipase inhibitors

Article Title: Isolation structural characterization and molecular docking analysis of bioactive phytoconstituents from Hiptage madablota Gaertn root as human pancreatic lipase inhibitors

Article References: Retnasamy, G., Adikay, S., Saravanakumar, A., Repudi, L., Nuli, M. V., Chagarlamudi, K., Jaini, P. K., & Gandla, K. (2026). Isolation structural characterization and molecular docking analysis of bioactive phytoconstituents from Hiptage madablota Gaertn root as human pancreatic lipase inhibitors. Discover Chemistry, 3(1), Article 563. https://doi.org/10.1007/s44371-026-01014-8

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01014-8

Keywords: Hiptage madablota, pancreatic lipase, molecular docking, phytochemistry, obesity, kaempferide, HPTLC, natural products, ADMET prediction, flavonoids, drug discovery, ethnopharmacology

The scale of the problem is enormous. According to the review, roots account for roughly 30 percent of the raw material consumed by the global medicinal and aromatic plant industry, and bark for about 13 percent. Harvesting these tissues almost always means uprooting or felling the entire plant. For slow-growing perennials used in Ayurveda, Siddha, Unani and Traditional Chinese Medicine, that is a death sentence repeated thousands of times a year. Excessive or careless bark removal disrupts water and nutrient transport so severely that trees often die, and illegal trade compounds the pressure on wild populations, eroding both species richness and genetic diversity.

The authors are careful to stress that substitution cannot be assumed from traditional reputation alone. The biosynthesis, transport and storage of secondary metabolites are typically organ-specific and dependent on tissue development, so the profile of a root or a piece of bark may differ dramatically from that of a leaf. Concentrations also shift with plant age, growth stage, season, genotype and environment. Their proposed standard is therefore rigorous: a candidate substitute must be validated by systematic comparative profiling of marker compounds using techniques such as high-performance thin-layer chromatography (HPTLC), high-performance liquid chromatography (HPLC) or liquid chromatography–tandem mass spectrometry (LC–MS/MS), supported by quantitative assays of total phenolics, flavonoids and other chemical classes.

The first case study is Myrica esculenta, the Himalayan bayberry known locally as kaphal, whose stem bark is used across Uttarakhand and neighboring regions for headaches, asthma, chronic coughs, wounds and toothaches. Comparative analysis found that stem bark does contain far more total phenolics—276.78 milligrams of gallic acid equivalents per gram of dry weight versus 31.24 for small branches—and more flavonoids, 121.68 versus 12.94 milligrams of quercetin equivalents per gram. Yet qualitative HPTLC profiling revealed congruent bands in both tissues, indicating that the same classes of secondary metabolites, including gallic acid, catechin, proanthocyanidins, myricanol and myricanone, are present in small branches. That chemical overlap, the authors note, matches what traditional healers already do when they substitute branches for bark, and it underpins the species’ antioxidant, anti-inflammatory and antimicrobial activities documented in fruit, leaf and bark extracts.

Pelargonium sidoides, the African geranium of South Africa and Lesotho, offers perhaps the most striking quantitative case. Its roots are the source of a widely used remedy for respiratory infections, and its coumarins and phenolic acids have been studied for antibacterial, immunomodulatory and even HIV-1 entry-inhibiting effects. When researchers compared wild and acclimatized plants using UPLC-MS/MS, the aerial parts outperformed the underground organs for all three marker phenolic acids. Wild aerial tissues contained 231.08 micrograms of gallic acid per gram of dry weight against 72.7 in underground parts, and protocatechuic acid was roughly 70-fold higher in wild aerial tissue than underground. Salicylic acid followed the same pattern. The authors conclude that these data directly support replacing root harvests with aerial harvests, a shift that would leave the perennial geophyte intact in the soil.

Warburgia salutaris, the endangered pepper-bark tree of southern and eastern Africa, shows that substitution can even improve yields. Its drimane-type sesquiterpenoids, warburganal and polygodial, are the compounds behind its reputation as one of Africa’s most valuable natural antimicrobials, used against coughs, malaria-like fevers, wounds and stomach ailments. Quantitative measurements found leaves yielding 0.05 percent polygodial and 0.06 percent warburganal, matching or exceeding bark yields of 0.03 and 0.06 percent, while a Venda genotype produced 0.04 and 0.09 percent respectively. Because leaves are harvested non-destructively and present a simpler extraction matrix than bark, the review describes leaf substitution as both conservation-friendly and commercially practical for this threatened Canellaceae species, whose extracts have also shown activity against Mycobacterium tuberculosis and, in the case of iso-mukaadial acetate, potent antimalarial effects with an in vitro IC50 of 0.44 micrograms per milliliter against Plasmodium falciparum.

The remaining two examples come from Asia. Litsea chinensis, a genus member used in Indian and Chinese traditional medicine for diarrhea, diabetes, inflammation and colds, showed a trade-off: heartwood carried more flavonoids, 100.32 versus 41.74 micrograms of quercetin equivalents per gram, but small branches carried more total phenolics, 64.13 versus 58.32 micrograms of gallic acid equivalents per gram. HPTLC profiles of hexane, ethyl acetate and ethanolic extracts revealed many shared bands between heartwood and branches, supporting branch substitution for a tree whose heartwood harvest is inherently lethal. Aegle marmelos, the bael tree sacred in India for five millennia, produced an even cleaner result: stem extracts contained 59.89 percent more total phenolics than root extracts, 21.64 percent more flavonoids, 13.58 percent more tannins, and nearly identical alkaloid levels, with thin-layer and high-performance liquid chromatography confirming umbelliferone and scopoletin in both organs. The authors conclude that bael stems are a viable stand-in for roots.

What makes the review more than a chemistry exercise is its policy framing. The authors align plant-part substitution with India’s Biological Diversity Act, the Convention on Biological Diversity, the Nagoya Protocol, WHO-IUCN-WWF conservation policy and United Nations Sustainable Development Goals 3, 13 and 15, which cover health, climate action and life on land. India’s National Medicinal Plants Board and the Central Council for Research in Ayurvedic Sciences, under the Ministry of AYUSH, already promote the scientific validation of substitutes for threatened, high-demand species, and the review itself was supported by a National Medicinal Plants Board project. In effect, substitution offers regulators a lever that cultivation programs alone cannot: it reduces demand pressure at the source while ex situ propagation and controlled-environment agriculture scale up supply.

The authors are candid about the gaps. Quantitative equivalence varies among species and even among genotypes, as the Pelargonium and Warburgia data show, and pharmacological equivalence—proof that a leaf extract performs like a bark extract in the body—still requires rigorous in vivo and in vitro pharmacodynamic and toxicological studies across broader disease models. Their future agenda calls for embedding substitution guidelines in national and international biodiversity and pharmaceutical regulations, training traditional healers, cultivators and industry stakeholders in standardized harvesting and quality control, extending the approach to additional high-value taxa and ecosystems with ecological mapping and community-based monitoring, and partnering with pharmaceutical and nutraceutical manufacturers to translate validated substitutions into scalable products. If those steps follow, the humble leaf—regrown every season while the tree stands—may become the pharmaceutical industry’s most sustainable raw material, and the difference between a medicinal forest that survives and one that is dug up, strip by strip, for medicine.

Subject of Research: Plant part substitution based on phytochemical equivalence as a conservation strategy for overharvested medicinal plants

Article Title: Plant part substitution as a sustainable conservation strategy for some medicinal plants based on phytochemical equivalence

Article References: Muley, M., Dondulkar, A., Ghagare, A., Meshram, S., Prasad, S., & Itankar, P. (2026). Plant part substitution as a sustainable conservation strategy for some medicinal plants based on phytochemical equivalence. Discover Plants, 3(1), Article 407. https://doi.org/10.1007/s44372-026-00875-8

Image Credits: AI Generated

DOI: 10.1007/s44372-026-00875-8

Keywords: medicinal plants, plant part substitution, phytochemical equivalence, conservation, HPTLC, HPLC, LC-MS/MS, bark harvesting, sustainable harvesting, Nagoya Protocol, ethnopharmacology, biodiversity

The review, led by Zaynab Ouadghiri and Othman El Faqer, together with colleagues in the Laboratory of Integrative Biology at the Faculty of Sciences Ain Chock, surveys the phytochemistry and biological activities of M. vulgare with particular emphasis on marrubiin, the furan labdane diterpene that gives the plant its characteristic bitterness and has become its most intensively studied molecule. The team’s synthesis covers antioxidant, anti-inflammatory, antimicrobial, antidiabetic, hepatoprotective, gastroprotective, cardioprotective, neuroprotective and antiproliferative effects reported across a large body of preclinical work. What emerges is a portrait of a chemically rich plant whose traditional uses are, in many cases, supported at least in principle by laboratory evidence, even as the leap to proven clinical therapy remains firmly out of reach.

The chemical arsenal of white horehound is central to the story. The plant produces a diverse suite of secondary metabolites, including diterpenoids, flavonoids, phenolic acids, tannins and volatile constituents, each class contributing differently to the observed pharmacology. Diterpenoids such as marrubiin and related labdane compounds dominate the pharmacological literature, while the phenolic fraction, rich in flavonoids and phenolic acids, underpins much of the antioxidant activity measured in extracts. Essential oils isolated from the aerial parts add antimicrobial and antifungal dimensions. This chemical diversity is a double-edged sword: it offers multiple pharmacological entry points, but it also means that extracts from different regions, harvested at different times and prepared by different methods can vary enormously in composition, complicating any attempt to compare studies or reproduce results.

Marrubiin itself has become something of a molecular celebrity in natural product research. First isolated from horehound in the nineteenth century, this bitter diterpene has been the subject of studies spanning cardiovascular protection, diabetes, inflammation and even cancer biology. Recent work highlighted in the review points to interactions with PPAR gamma, a nuclear receptor central to glucose and lipid metabolism, offering a mechanistic explanation for reported antidiabetic and anti-inflammatory effects. Researchers have also engineered delivery systems to exploit the molecule, including marrubiin-loaded solid lipid nanoparticles that showed cardioprotective effects in endothelial cell models exposed to inflammatory challenge. On the biosynthetic side, plant biologists have identified cytochrome P450 enzymes involved in marrubiin production, opening the door to metabolic engineering approaches that could yield standardized supplies of the compound without depending on variable wild harvests.

The cardiovascular findings are among the most intriguing. In isolated rat heart models, aqueous fractions of M. vulgare demonstrated protective effects against ischaemia-reperfusion injury, the cascade of damage that occurs when blood supply returns to oxygen-starved tissue. Separate studies using methanolic extracts reported inhibition of inflammatory responses and prevention of cardiomyocyte fibrosis in chemically induced myocardial infarction in rats. Extracts have also shown inhibitory activity against angiotensin I converting enzyme, the same target exploited by widely prescribed blood pressure medications. These results align neatly with the plant’s long history of use for heart complaints in Moroccan, Iranian and European traditional medicine, and they suggest that horehound-derived compounds could eventually yield leads for cardiovascular drug development, though the authors are careful to stress that isolated organ and cell models are a long way from intact human physiology.

Metabolic effects form another major pillar of the evidence. In streptozotocin-induced diabetic rats, methanolic extracts of the plant ameliorated both hyperglycemia and dyslipidemia, the twin metabolic disturbances that define type 2 diabetes and its complications. In vitro assays have shown inhibition of alpha-glucosidase, an intestinal enzyme targeted by antidiabetic drugs, while metabolomics-based studies of Algerian medicinal plants identified horehound extracts as particularly active in this regard. The anti-inflammatory data are similarly extensive, spanning carrageenan-induced paw edema in rats, antiarthritic models, antinociceptive testing and even studies of neuropathic pain following sciatic nerve injury. Immunomodulatory effects have been documented in animal models of bacterial infection, where leaf extracts altered immune responses, adding another layer to the plant’s pharmacological profile.

Perhaps the most medically ambitious claims concern protection of the brain, the liver and the gut, and the plant’s possible anticancer potential. Rat studies using scopolamine-induced cognitive impairment, a common model for memory deficits, found that horehound extracts improved spatial working memory and reduced oxidative stress damage, with behavioral improvements matched by biochemical changes. Phenylethanoid glycoside-rich extracts have shown anti-Alzheimer’s activity in vitro and in computational docking studies. In cancer research, ethanolic extracts of the plant induced proliferation arrest, apoptosis and cytoprotective autophagy in cancer cell lines, while methanolic fractions from several Marrubium species showed cytotoxic activity against melanoma cells that was independent of their antioxidant capacity, hinting at distinct mechanisms. Cytotoxicity evaluations and zebrafish embryo toxicity screening have begun to map the safety boundaries of these effects, and studies of burn wound healing have explored topical applications in combination with other medicinal plants.

Yet the review is emphatic that enthusiasm must be tempered by the quality of the underlying evidence. Nearly everything known about the pharmacology of M. vulgare comes from in vitro experiments and animal studies; clinical data in humans remain scarce to nonexistent. The authors highlight considerable variability in extract composition and experimental protocols across the literature, which makes it difficult to compare doses, identify the true active principles or establish dose-response relationships. Information on pharmacokinetics, meaning how the plant’s compounds are absorbed, distributed, metabolized and excreted in the body, is limited, as is long-term safety data. Without chemically standardized preparations, it is impossible to know whether a tea, a tincture and a subcritical extract are delivering anything remotely comparable, and mechanism-specific validation, in which a defined compound is shown to act through a defined molecular pathway, remains the exception rather than the rule.

The path forward sketched by the Moroccan team is rigorous and conventional in the best sense: chemically standardized preparations, rigorous mechanistic studies, comprehensive toxicological assessment and, only where the preclinical case justifies it, well-designed clinical trials. Advances in extraction technology, from microwave-assisted and ultrasound-assisted methods optimized by experimental design to spray drying of subcritical extracts, are making it increasingly feasible to produce consistent, high-quality horehound preparations with defined marrubiin content. Combined with metabolomic fingerprinting and in silico approaches that can predict molecular targets before bench work begins, these tools could transform horehound from a folk remedy of variable potency into a reproducible source of drug leads.

For now, white horehound sits in a familiar position for medicinal plants: rich in promise, validated by tradition and preclinical data, but unproven at the bedside. The review’s value lies precisely in its honesty about that gap. It consolidates a sprawling literature, connects the plant’s chemistry to plausible mechanisms for its traditional uses in respiratory, gastrointestinal, cardiovascular and inflammatory disorders, and lays out what must happen before marrubiin or any of its chemical cousins can be taken seriously as therapeutic agents. In an era of rising diabetes, cardiovascular disease and drug-resistant infections, the humble horehound’s chemical repertoire deserves the systematic attention it is finally receiving, and the next decade of standardized, mechanistically grounded research will determine whether this ancient bitter herb becomes a modern medicine or remains a fascinating footnote in ethnopharmacology.

Subject of Research: Phytochemistry and pharmacological activities of the medicinal plant Marrubium vulgare (white horehound) and its major diterpene marrubiin

Article Title: Comprehensive analysis of the pharmacological potentials of Marrubium vulgare (white horehound): a recent overview of phytochemistry and biological activities

Article References: Ouadghiri, Z., El Faqer, O., Wahnou, H., Rais, S., & Mtairag, E. M. (2026). Comprehensive analysis of the pharmacological potentials of Marrubium vulgare (white horehound): a recent overview of phytochemistry and biological activities. The Science of Nature, 113(5), Article 107. https://doi.org/10.1007/s00114-026-02156-6

Image Credits: AI Generated

DOI: 10.1007/s00114-026-02156-6

Keywords: Marrubium vulgare, white horehound, marrubiin, phytochemistry, medicinal plants, ethnopharmacology, antioxidant activity, anti-inflammatory, antidiabetic, cardioprotection, diterpenoids, preclinical research

The research, published in BMC Complementary Medicine and Therapies, was carried out by an international team of pharmacognosists and analytical chemists working across institutions in Egypt, Morocco, Finland, and elsewhere. Led by Ahmed Zayed of Tanta University in Egypt together with Meryem El Jemli of Mohammed VI University of Sciences and Health in Casablanca, the investigators assembled 21 different herbal teas that Moroccans traditionally drink to help control blood sugar. Their goal was not simply to confirm that the teas are popular, but to open them up at the molecular level and ask a deceptively simple question: what exactly is in the cup, and could any of it plausibly interfere with the biochemical processes that drive high blood glucose after a meal?

To answer that question, the team deployed high-performance liquid chromatography coupled with mass spectrometry, or HPLC-MS, a technique that acts like an extraordinarily sensitive sorting machine for small molecules. The tea extracts are pushed through a column that separates individual compounds based on their chemical affinities, and each fraction is then weighed and identified by its mass-to-charge signature. This allowed the researchers to build a molecular census of each infusion, identifying and quantifying the phenolic compounds, a broad family of plant secondary metabolites that includes flavonoids, phenolic acids, and tannins, all of which are known for their antioxidant behavior and, in some cases, their ability to modulate human enzymes.

The analytical results revealed striking differences from plant to plant. Peppermint, Mentha × piperita, topped the table for total phenolic content, packing 883.2 milligrams of gallic acid equivalents per gram of dry weight, with the Moroccan endemic thyme species Thymus broussonetii close behind at 746.8 milligrams per gram. For readers unfamiliar with the unit, gallic acid equivalents, abbreviated GAE, are a standard yardstick that expresses the total reducing capacity of a plant extract as if it were all one reference antioxidant, allowing chemists to compare apples to oranges, or in this case, mints to thymes. Concentrations approaching or exceeding 700 milligrams per gram mean that these dried herbs are, on a weight basis, extraordinarily dense reservoirs of reactive phenolic chemistry.

Antioxidant capacity was assessed with three complementary assays, each probing a different facet of antioxidant behavior. The DPPH and ABTS tests measure how effectively a compound scavenges synthetic free radicals in solution, while the FRAP assay measures reducing power, the ability to donate electrons to ferric iron. No single assay tells the whole story, which is precisely why the team used all three. Across the panel, antioxidant performance varied substantially, with Thymus broussonetii showing a particularly strong FRAP value of 423.6 micrograms per milliliter and Mentha rotundifolia, apple mint, demonstrating significant reducing capacity at 162.6 micrograms per milliliter. Critically, total phenolic content correlated strongly and positively with antioxidant indices across all 21 teas, with correlation coefficients ranging from 0.93 to 0.96. In statistical terms, that is a near-lockstep relationship, strongly suggesting that the phenolics themselves, rather than some other class of molecules, are the engines of the observed antioxidant activity.

But antioxidant activity alone would be a familiar and somewhat underwhelming finding. The more provocative part of the study concerns carbohydrate-digesting enzymes. After a starchy meal, the digestive enzymes alpha-amylase, secreted by the salivary glands and pancreas, and alpha-glucosidase, anchored in the brush border of the small intestine, work in sequence to chop long carbohydrate chains down to glucose that can be absorbed into the bloodstream. Drugs such as acarbose exploit this biology by inhibiting these enzymes, blunting the post-meal glucose spike that is so dangerous for people with type 2 diabetes. If plant phenolics can do something similar, even modestly, they could help explain the ethnomedicinal reputation of these teas.

The enzyme inhibition results are where the study turns genuinely eye-catching. Pelargonium graveolens, rose-scented geranium, a staple of Moroccan gardens and infusions, inhibited alpha-amylase with an IC50 of just 2.98 micrograms per milliliter. The IC50 is the concentration of an inhibitor needed to halve enzyme activity, so lower numbers mean more potent inhibition, and a value under three micrograms per milliliter for a crude plant extract is, on its face, a striking figure. On the alpha-glucosidase side, spearmint, Mentha viridis, and Calamintha officinalis, calamint, emerged as the standouts, with IC50 values of 1.9 and 1.2 micrograms per milliliter respectively. These are the kinds of numbers that make pharmacognosists sit up and pay attention, because crude extracts rarely achieve such low IC50 values against clinically relevant enzymes.

The correlation analysis added an intriguing chemical clue to the story. The researchers found negative correlations between the abundance of two specific phenolics, the flavonoid rutin and the simple phenolic acid gallic acid, and the alpha-amylase IC50 values, with coefficients of minus 0.49 and minus 0.44 respectively. Because a lower IC50 means stronger inhibition, a negative correlation implies that teas richer in rutin and gallic acid tended to be more potent amylase blockers. Rutin, a glycoside of the flavonol quercetin, and gallic acid are both known from prior biochemical literature to interact with digestive enzymes, and these new correlation data are consistent with the idea that they contribute meaningfully to the observed activity, though correlations across a panel of 21 extracts cannot by themselves prove causation for any single compound.

The authors are careful, and rightly so, to frame what this study does and does not demonstrate. Everything reported here took place in vitro, meaning in test tubes and microplates rather than in living bodies. A potent enzyme inhibitor in a cuvette may behave very differently once it passes through the stomach, encounters liver metabolism, and reaches the intestine at unknown concentrations, a question of pharmacokinetics that in vitro assays simply cannot address. The team explicitly notes that the findings do not establish therapeutic efficacy and that in vivo, mechanistic, pharmacokinetic, and clinical studies are required before any claims about efficacy, safety, or clinical relevance can be made. They also observed that the variability among samples may reflect differences in plant species as well as environmental and agronomic factors such as growing conditions and harvest timing, a reminder that herbal preparations are chemically inconsistent in ways that standardized pharmaceuticals are not.

Even with those caveats firmly in place, the study represents a meaningful step in a larger scientific project: using rigorous analytical chemistry to take traditional knowledge seriously as a source of leads rather than dismissing it as folklore, or credulously accepting it as medicine. Morocco’s herbal tea culture is a living pharmacopoeia refined over centuries, and techniques like HPLC-MS now allow researchers to read that pharmacopoeia molecule by molecule. The 21 infusions examined here vary enormously in their phenolic makeups and biological activities, and that variation itself is information, pointing toward which species deserve deeper investigation, which compounds such as rutin and gallic acid merit isolation and mechanistic testing, and how traditional preparation methods might influence the chemistry that ends up in the glass. For now, the safest conclusion is the one the data support: some of Morocco’s most beloved digestive teas are unusually rich in bioactive phenolics and surprisingly effective at blocking the enzymes that digest starch in the laboratory. Whether a daily glass of mint tea can actually move blood sugar numbers in a person with diabetes remains an open question, one that only carefully designed clinical trials can answer. But the bridge between the Moroccan tea tray and the modern pharmacology of glucose control has never looked more worth crossing.

Subject of Research: Phenolic composition and anti-diabetic enzyme inhibitory activity of traditional Moroccan herbal teas

Article Title: Ethnopharmacological insights into type 2 diabetes management by traditional Moroccan herbal teas: HPLC-MS characterization of phenolic compounds and their related antioxidant and enzyme inhibitory activities

Article References: Zayed, A., El Jemli, M., Kharbach, M., Faouzi, M. E. A., Radwan, R. A., & Ezzat, S. M. (2026). Ethnopharmacological insights into type 2 diabetes management by traditional Moroccan herbal teas: HPLC-MS characterization of phenolic compounds and their related antioxidant and enzyme inhibitory activities. BMC Complementary Medicine and Therapies, 26(1), Article 279. https://doi.org/10.1186/s12906-026-05588-9

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05588-9

Keywords: Moroccan herbal teas, type 2 diabetes, HPLC-MS, phenolic compounds, antioxidant activity, alpha-amylase inhibition, alpha-glucosidase inhibition, rutin, gallic acid, ethnopharmacology, Mentha, Thymus broussonetii

The scientific motivation is stark. Breast cancer is the leading cause of cancer-related death in women worldwide, accounting for roughly 2.3 million new cases and nearly 685,000 deaths in 2020, about 30 percent of all cancers diagnosed in women. The burden falls especially hard in sub-Saharan Africa. In Cameroon alone, more than 4,000 new cases are recorded annually and over 2,000 women die of the disease. Standard treatments, including surgery, chemotherapy and hormone-blocking drugs such as tamoxifen, save lives but carry well-known liabilities: damage to healthy liver and kidney tissue, increased risk of secondary cancers, drug resistance, tumor recurrence and high costs. Against that backdrop, an estimated 80 percent of populations in Africa and Asia still rely on medicinal plants for primary health care, making rigorous scientific evaluation of those remedies a matter of both public health and drug discovery.

The research team, working with plant material harvested in Ngaoundere in Cameroon’s Adamawa region and authenticated at the National Herbarium of Cameroon, prepared two crude extracts from the tree’s stem bark: an aqueous extract made by soaking powdered bark in water for 24 hours, and a hydro-ethanolic extract using a 20 percent water, 80 percent ethanol mixture over 72 hours. Phytochemical profiling revealed a rich inventory of secondary metabolites in both preparations. Polyphenols dominated, at 348.78 milligrams of ascorbic acid equivalents per gram of dry weight in the aqueous extract and 434.22 in the ethanolic one, followed by flavonoids, tannins and flavonols. Consistent with this chemistry, both extracts showed potent free radical scavenging in the DPPH assay, with half-maximal inhibitory concentrations of roughly 19.7 and 17.2 micrograms per milliliter, and considerable ferric reducing power, confirming their capacity to neutralize the reactive oxygen species implicated in cancer initiation.

The in vitro results were striking. Tested against two human breast cancer cell lines, the estrogen-sensitive MCF-7 line and the aggressive triple-negative MDA-MB-231 line, both extracts inhibited growth in a dose-dependent manner within 24 hours. The ethanolic extract was the more potent, halting growth of MCF-7 cells at an IC50 of 41.63 micrograms per milliliter and MDA-MB-231 cells at 44.27, while the aqueous extract required 59.43 and 67.55 micrograms per milliliter respectively. Crucially, both extracts were far less toxic to non-cancerous human mammary epithelial cells, with IC50 values near 150 micrograms per milliliter, yielding a selectivity index above 2.5. That selectivity is the holy grail of cytotoxic drug development: a compound that kills cancer cells while sparing healthy ones.

Mechanistically, the extracts appear to work through two complementary routes. Flow cytometry showed that the aqueous extract pushed MCF-7 cells to accumulate in the DNA synthesis phase, raising the S-phase population from 15.75 percent in controls to 20.85 percent, while the ethanolic extract arrested cells at the G2/M checkpoint, increasing that population from 30.35 to 36.4 percent. Blocking the cell cycle at these points prevents mitotic entry and typically primes cells for apoptotic death. Fluorescence microscopy using acridine orange and propidium iodide co-staining confirmed that the aqueous extract triggered the morphological hallmarks of apoptosis, including membrane blebbing, chromatin condensation and the formation of apoptotic bodies, in both cancer cell lines. Apoptosis, or programmed cell death, is the preferred mechanism of cancer cell killing because, unlike necrosis, it minimizes inflammation and damage to surrounding tissue. Interestingly, neither extract significantly altered the cell cycle distribution of the triple-negative MDA-MB-231 cells, a reminder that the more aggressive molecular subtype may resist checkpoint regulation even as it succumbs to the extracts’ cytotoxic effects.

The decisive test came in living animals. The team induced mammary tumors in female Wistar rats using 7,12-dimethylbenz(a)anthracene, or DMBA, a polycyclic aromatic hydrocarbon carcinogen injected into the mammary region at 50 milligrams per kilogram of body weight. Every DMBA-exposed control rat developed tumors within the 140-day observation window, and two animals died. Rats treated daily by gavage with the aqueous bark extract at 75, 150 or 300 milligrams per kilogram fared dramatically better. Tumor incidence fell to 62.5 percent at the lowest dose and 25 percent at the middle dose, while tumor burden inhibition exceeded 85 percent at all doses, peaking at 99 percent at 150 milligrams per kilogram. Tamoxifen, the reference drug at 3.3 milligrams per kilogram, reduced tumor incidence to 37.5 percent and tumor burden by 44 percent. The extract also lowered tumor volume and slashed serum levels of CA15-3, a MUC-1-derived glycoprotein overexpressed in roughly 90 percent of breast cancers and widely used to monitor disease progression, to a degree comparable with tamoxifen.

Equally important was what the extract did to the biochemical environment that fuels tumor growth. DMBA exposure devastated the rats’ antioxidant defenses, elevating malondialdehyde, a marker of lipid peroxidation, while depleting glutathione and suppressing the activities of superoxide dismutase and catalase, the enzymes that detoxify superoxide anions and hydrogen peroxide. The bark extract reversed all of these changes, restoring redox homeostasis and protecting cell membranes from oxidative damage. It also tamed inflammation: DMBA raised serum levels of the pro-inflammatory cytokines TNF-alpha, IL-6, IFN-gamma and the angiogenic factor VEGF, all of which promote tumor progression and epithelial-to-mesenchymal transition through signaling pathways such as NF-kappaB and JNK. Treatment with the extract significantly reduced TNF-alpha, IL-6 and VEGF in a dose-dependent manner and boosted the anti-inflammatory cytokine IL-10 at the middle dose, suggesting it interferes with the inflammatory circuitry that enables tumors to grow, invade and recruit blood vessels.

Safety signals were reassuring across multiple fronts. Unlike tamoxifen, which caused progressive weight loss in treated rats consistent with its known anorectic effects, the extract produced no significant change in body weight over nearly five months of daily dosing. DMBA had elevated liver enzymes ALT and AST, alkaline phosphatase, bilirubin, urea and creatinine, hallmarks of hepatic and renal injury, and the extract normalized these markers in a dose-dependent fashion. Hematological analysis told a similar story: DMBA induced leukocytosis, anemia and elevated platelet counts, and the extract restored white blood cell, red blood cell, hematocrit and platelet values toward normal. Histology of the mammary glands showed that treated tumors lost their aggressive architecture, with only rare, loose tumor cell plaques persisting within necrotic areas at the highest dose. The authors note, however, that further work is needed to confirm activation of the intrinsic apoptotic pathway through caspase-9 and Bcl-2 family proteins, to characterize anti-estrogenic mechanisms directly, and to standardize the extract chromatographically with computational ADME modeling.

The study’s significance extends beyond a single plant. It demonstrates a rigorous pipeline, from traditional healer’s remedy to phytochemical characterization, selective cytotoxicity, mechanistic cell biology and long-term animal chemoprevention, that could be applied to the vast untested pharmacopoeia of African and Asian medicinal flora. If the polyphenol- and flavonoid-rich chemistry of Erythrina excelsa can be standardized, its active molecules isolated and its efficacy and safety confirmed in further preclinical and eventually clinical studies, a roadside tree of Cameroon may yet contribute a new, affordable and better-tolerated weapon against a disease that kills a woman somewhere in the world roughly every minute. For now, the message is one of validated promise: a remedy rooted in local knowledge has passed its first serious scientific examinations with remarkable results.

Subject of Research: Evaluation of the anti-breast cancer activity of Erythrina excelsa bark extracts in vitro and in vivo

Article Title: An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts

Article References: Walantini, J., Sipping, M. T. K., Ymele, M. N., Rebe, R. N., Yaya, J. A. G., Ndinteh, D. T., Njamen, D., & Zingue, S. (2026). An In Vitro and In Vivo Assessment of the Anti‐Breast Cancer Activity of Erythrina excelsa Baker (Fabaceae) Bark Extracts. Cancer Reports, 9(9), Article e70642. https://doi.org/10.1002/cnr2.70642

Image Credits: AI Generated

DOI: 10.1002/cnr2.70642

Keywords: breast cancer, Erythrina excelsa, chemoprevention, polyphenols, DMBA, apoptosis, antioxidants, tamoxifen, natural products, cell cycle arrest, CA15-3, ethnopharmacology